ID   HCDH_HUMAN              Reviewed;         314 AA.
AC   Q16836; J3KQ17; O00324; O00397; O00753; Q4W5B4;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   02-NOV-2010, sequence version 3.
DT   10-MAY-2017, entry version 189.
DE   RecName: Full=Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial;
DE            Short=HCDH;
DE            EC=1.1.1.35;
DE   AltName: Full=Medium and short-chain L-3-hydroxyacyl-coenzyme A dehydrogenase;
DE   AltName: Full=Short-chain 3-hydroxyacyl-CoA dehydrogenase;
DE   Flags: Precursor;
GN   Name=HADH; Synonyms=HAD, HADHSC, SCHAD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS PRO-86 AND
RP   HIS-152.
RC   TISSUE=Liver;
RX   PubMed=8687463; DOI=10.1006/bbrc.1996.0961;
RA   Vredendaal P.J.C.M., van den Berg I.E.T., Malingre H.E.M.,
RA   Stroobants A.K., Oldeweghuis D.E.M., Berger R.;
RT   "Human short-chain L-3-hydroxyacyl-CoA dehydrogenase: cloning and
RT   characterization of the coding sequence.";
RL   Biochem. Biophys. Res. Commun. 223:718-723(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 2), NUCLEOTIDE
RP   SEQUENCE [MRNA] OF 7-314 (ISOFORM 1), AND VARIANT PRO-86.
RC   TISSUE=Skeletal muscle;
RA   Shi Y., Samuel S.J., Lee W., Yu C.H., Zhang W., Lachaal M., Jung C.Y.;
RT   "Cloning of a L-3-hydroxyacyl CoA dehydrogenase that binds to GLUT4
RT   glucose transporter cytoplasmic C-terminus: possible crosstalk between
RT   glucose transport and fatty acid metabolism.";
RL   Submitted (NOV-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT PRO-86.
RA   O'Brien L.K., Sims H.F., Strauss A.W.;
RT   "Human short chain L-3-hydroxyacyl-CoA dehydrogenase.";
RL   Submitted (SEP-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   PRO-86.
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-185; LYS-202; LYS-241 AND
RP   LYS-312, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 13-314 IN COMPLEX WITH
RP   SUBSTRATE AND NAD.
RX   PubMed=10231530; DOI=10.1021/bi9829027;
RA   Barycki J.J., O'Brien L.K., Bratt J.M., Zhang R., Sanishvili R.,
RA   Strauss A.W., Banaszak L.J.;
RT   "Biochemical characterization and crystal structure determination of
RT   human heart short chain L-3-hydroxyacyl-CoA dehydrogenase provide
RT   insights into catalytic mechanism.";
RL   Biochemistry 38:5786-5798(1999).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 13-314 IN COMPLEX WITH
RP   SUBSTRATE AND NAD.
RX   PubMed=10840044; DOI=10.1074/jbc.M004669200;
RA   Barycki J.J., O'Brien L.K., Strauss A.W., Banaszak L.J.;
RT   "Sequestration of the active site by interdomain shifting.
RT   Crystallographic and spectroscopic evidence for distinct conformations
RT   of L-3-hydroxyacyl-CoA dehydrogenase.";
RL   J. Biol. Chem. 275:27186-27196(2000).
RN   [12]
RP   REVIEW.
RX   PubMed=16176262; DOI=10.1111/j.1742-4658.2005.04911.x;
RA   Yang S.-Y., He X.-Y., Schulz H.;
RT   "3-hydroxyacyl-CoA dehydrogenase and short chain 3-hydroxyacyl-CoA
RT   dehydrogenase in human health and disease.";
RL   FEBS J. 272:4874-4883(2005).
RN   [13]
RP   VARIANTS HADH DEFICIENCY THR-40 AND GLU-57.
RA   O'Brien L.K., Rinaldo P., Sims H.F., Alonso E.M., Charrow J.,
RA   Jones P.M., Bennett M.J., Barycki J.J., Banaszak L.J., Strauss A.W.;
RT   "Fulminant hepatic failure associated with mutations in the medium and
RT   short chain L-3-hydroxyacyl-CoA dehydrogenase gene.";
RL   J. Inherit. Metab. Dis. 23 Suppl. 1:127-127(2000).
RN   [14]
RP   VARIANT HHF4 LEU-258, AND CHARACTERIZATION OF VARIANT HHF4 LEU-258.
RX   PubMed=11489939; DOI=10.1172/JCI200111294;
RA   Clayton P.T., Eaton S., Aynsley-Green A., Edginton M., Hussain K.,
RA   Krywawych S., Datta V., Malingre H.E.M., Berger R.,
RA   van den Berg I.E.T.;
RT   "Hyperinsulinism in short-chain L-3-hydroxyacyl-CoA dehydrogenase
RT   deficiency reveals the importance of beta-oxidation in insulin
RT   secretion.";
RL   J. Clin. Invest. 108:457-465(2001).
CC   -!- FUNCTION: Plays an essential role in the mitochondrial beta-
CC       oxidation of short chain fatty acids. Exerts it highest activity
CC       toward 3-hydroxybutyryl-CoA.
CC   -!- CATALYTIC ACTIVITY: (S)-3-hydroxyacyl-CoA + NAD(+) = 3-oxoacyl-CoA
CC       + NADH.
CC   -!- PATHWAY: Lipid metabolism; fatty acid beta-oxidation.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:10231530,
CC       ECO:0000269|PubMed:10840044}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q16836-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q16836-2; Sequence=VSP_016551, VSP_016552;
CC         Note=Ref.2 (AAB58153) sequence is in conflict in position:
CC         41:L->P. Ref.2 (AAB58153) sequence is in conflict in position:
CC         56:R->H. {ECO:0000305};
CC       Name=3;
CC         IsoId=Q16836-3; Sequence=VSP_016552;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in liver, kidney, pancreas, heart
CC       and skeletal muscle.
CC   -!- PTM: Succinylation at Lys-81, adjacent to a coenzyme A binding
CC       site. Desuccinylated by SIRT5 (By similarity). {ECO:0000250}.
CC   -!- DISEASE: 3-alpha-hydroxyacyl-CoA dehydrogenase deficiency (HADH
CC       deficiency) [MIM:231530]: A metabolic disorder with various
CC       clinical presentations including hypoglycemia,
CC       hepatoencephalopathy, myopathy or cardiomyopathy, and in some
CC       cases sudden death. {ECO:0000269|Ref.13}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Familial hyperinsulinemic hypoglycemia 4 (HHF4)
CC       [MIM:609975]: Most common cause of persistent hypoglycemia in
CC       infancy. Unless early and aggressive intervention is undertaken,
CC       brain damage from recurrent episodes of hypoglycemia may occur.
CC       HHF4 should be easily recognizable by analysis of acylcarnitine
CC       species and that this disorder responds well to treatment with
CC       diazoxide. It provides the first 'experiment of nature' that links
CC       impaired fatty acid oxidation to hyperinsulinism and that provides
CC       support for the concept that a lipid signaling pathway is
CC       implicated in the control of insulin secretion.
CC       {ECO:0000269|PubMed:11489939}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the 3-hydroxyacyl-CoA dehydrogenase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X96752; CAA65528.1; -; mRNA.
DR   EMBL; AF001902; AAB54008.1; -; mRNA.
DR   EMBL; AF001903; AAB54009.1; -; mRNA.
DR   EMBL; AF001904; AAB58153.1; -; Genomic_DNA.
DR   EMBL; AF095703; AAD13581.1; -; Genomic_DNA.
DR   EMBL; AC114733; AAY41050.1; -; Genomic_DNA.
DR   EMBL; AC118062; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000306; AAH00306.1; -; mRNA.
DR   CCDS; CCDS3678.1; -. [Q16836-1]
DR   CCDS; CCDS54790.1; -. [Q16836-3]
DR   PIR; JC4879; JC4879.
DR   RefSeq; NP_001171634.2; NM_001184705.2.
DR   RefSeq; NP_005318.3; NM_005327.4.
DR   UniGene; Hs.438289; -.
DR   PDB; 1F0Y; X-ray; 1.80 A; A/B=13-314.
DR   PDB; 1F12; X-ray; 2.40 A; A/B=13-314.
DR   PDB; 1F14; X-ray; 2.30 A; A/B=13-314.
DR   PDB; 1F17; X-ray; 2.30 A; A/B=13-314.
DR   PDB; 1IL0; X-ray; 2.20 A; A/B=13-314.
DR   PDB; 1LSJ; X-ray; 2.50 A; A/B=13-314.
DR   PDB; 1LSO; X-ray; 2.60 A; A/B=13-314.
DR   PDB; 1M75; X-ray; 2.30 A; A/B=13-314.
DR   PDB; 1M76; X-ray; 2.15 A; A/B=13-314.
DR   PDB; 2HDH; X-ray; 2.20 A; A/B=24-314.
DR   PDB; 3HAD; X-ray; 2.00 A; A/B=13-314.
DR   PDB; 3RQS; X-ray; 2.00 A; A/B=1-314.
DR   PDBsum; 1F0Y; -.
DR   PDBsum; 1F12; -.
DR   PDBsum; 1F14; -.
DR   PDBsum; 1F17; -.
DR   PDBsum; 1IL0; -.
DR   PDBsum; 1LSJ; -.
DR   PDBsum; 1LSO; -.
DR   PDBsum; 1M75; -.
DR   PDBsum; 1M76; -.
DR   PDBsum; 2HDH; -.
DR   PDBsum; 3HAD; -.
DR   PDBsum; 3RQS; -.
DR   ProteinModelPortal; Q16836; -.
DR   SMR; Q16836; -.
DR   BioGrid; 109283; 23.
DR   IntAct; Q16836; 3.
DR   MINT; MINT-5004681; -.
DR   DrugBank; DB03612; 3-Hydroxybutyryl-Coenzyme A.
DR   DrugBank; DB03059; Acetoacetyl-Coenzyme A.
DR   DrugBank; DB00157; NADH.
DR   SwissLipids; SLP:000001250; -.
DR   iPTMnet; Q16836; -.
DR   PhosphoSitePlus; Q16836; -.
DR   BioMuta; HADH; -.
DR   DMDM; 311033442; -.
DR   REPRODUCTION-2DPAGE; IPI00298406; -.
DR   UCD-2DPAGE; Q16836; -.
DR   EPD; Q16836; -.
DR   MaxQB; Q16836; -.
DR   PeptideAtlas; Q16836; -.
DR   PRIDE; Q16836; -.
DR   TopDownProteomics; Q16836-1; -. [Q16836-1]
DR   DNASU; 3033; -.
DR   Ensembl; ENST00000309522; ENSP00000312288; ENSG00000138796. [Q16836-1]
DR   Ensembl; ENST00000603302; ENSP00000474560; ENSG00000138796. [Q16836-3]
DR   GeneID; 3033; -.
DR   KEGG; hsa:3033; -.
DR   UCSC; uc003hyq.4; human. [Q16836-1]
DR   CTD; 3033; -.
DR   DisGeNET; 3033; -.
DR   GeneCards; HADH; -.
DR   GeneReviews; HADH; -.
DR   HGNC; HGNC:4799; HADH.
DR   HPA; HPA039588; -.
DR   HPA; HPA043888; -.
DR   MalaCards; HADH; -.
DR   MIM; 231530; phenotype.
DR   MIM; 601609; gene.
DR   MIM; 609975; phenotype.
DR   neXtProt; NX_Q16836; -.
DR   OpenTargets; ENSG00000138796; -.
DR   Orphanet; 71212; Hyperinsulinism due to short chain 3-hydroxylacyl-CoA dehydrogenase deficiency.
DR   PharmGKB; PA29173; -.
DR   GeneTree; ENSGT00870000136389; -.
DR   HOGENOM; HOG000141498; -.
DR   HOVERGEN; HBG000832; -.
DR   InParanoid; Q16836; -.
DR   KO; K00022; -.
DR   PhylomeDB; Q16836; -.
DR   TreeFam; TF300886; -.
DR   BioCyc; MetaCyc:HS06563-MONOMER; -.
DR   BRENDA; 1.1.1.35; 2681.
DR   Reactome; R-HSA-77310; Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA.
DR   Reactome; R-HSA-77346; Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA.
DR   Reactome; R-HSA-77348; Beta oxidation of octanoyl-CoA to hexanoyl-CoA.
DR   Reactome; R-HSA-77350; Beta oxidation of hexanoyl-CoA to butanoyl-CoA.
DR   Reactome; R-HSA-77352; Beta oxidation of butanoyl-CoA to acetyl-CoA.
DR   SABIO-RK; Q16836; -.
DR   UniPathway; UPA00659; -.
DR   ChiTaRS; HADH; human.
DR   EvolutionaryTrace; Q16836; -.
DR   GeneWiki; Hydroxyacyl-Coenzyme_A_dehydrogenase; -.
DR   GenomeRNAi; 3033; -.
DR   PRO; PR:Q16836; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000138796; -.
DR   CleanEx; HS_HADH; -.
DR   ExpressionAtlas; Q16836; baseline and differential.
DR   Genevisible; Q16836; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:LIFEdb.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:Ensembl.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003857; F:3-hydroxyacyl-CoA dehydrogenase activity; TAS:Reactome.
DR   GO; GO:0070403; F:NAD+ binding; IEA:InterPro.
DR   GO; GO:0006635; P:fatty acid beta-oxidation; TAS:Reactome.
DR   GO; GO:0046676; P:negative regulation of insulin secretion; IEA:Ensembl.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0032868; P:response to insulin; IEA:Ensembl.
DR   Gene3D; 1.10.1040.10; -; 1.
DR   InterPro; IPR022694; 3-OHacyl-CoA_DH.
DR   InterPro; IPR006180; 3-OHacyl-CoA_DH_CS.
DR   InterPro; IPR006176; 3-OHacyl-CoA_DH_NAD-bd.
DR   InterPro; IPR006108; 3HC_DH_C.
DR   InterPro; IPR008927; 6-PGluconate_DH_C-like.
DR   InterPro; IPR013328; 6PGD_dom_2.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   Pfam; PF00725; 3HCDH; 1.
DR   Pfam; PF02737; 3HCDH_N; 1.
DR   PIRSF; PIRSF000105; HCDH; 1.
DR   SUPFAM; SSF48179; SSF48179; 1.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   PROSITE; PS00067; 3HCDH; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Disease mutation; Fatty acid metabolism; Lipid metabolism;
KW   Mitochondrion; NAD; Oxidoreductase; Polymorphism; Reference proteome;
KW   Transit peptide.
FT   TRANSIT       1     12       Mitochondrion.
FT   CHAIN        13    314       Hydroxyacyl-coenzyme A dehydrogenase,
FT                                mitochondrial.
FT                                /FTId=PRO_0000007406.
FT   NP_BIND      34     39       NAD. {ECO:0000269|PubMed:10231530,
FT                                ECO:0000269|PubMed:10840044}.
FT   BINDING      57     57       NAD. {ECO:0000269|PubMed:10231530,
FT                                ECO:0000269|PubMed:10840044}.
FT   BINDING      73     73       Coenzyme A.
FT   BINDING      80     80       Coenzyme A.
FT   BINDING     122    122       NAD. {ECO:0000269|PubMed:10231530,
FT                                ECO:0000269|PubMed:10840044}.
FT   BINDING     127    127       NAD. {ECO:0000269|PubMed:10231530,
FT                                ECO:0000269|PubMed:10840044}.
FT   BINDING     149    149       Coenzyme A.
FT   BINDING     149    149       NAD. {ECO:0000269|PubMed:10231530,
FT                                ECO:0000269|PubMed:10840044}.
FT   BINDING     173    173       NAD. {ECO:0000269|PubMed:10231530,
FT                                ECO:0000269|PubMed:10840044}.
FT   BINDING     305    305       NAD. {ECO:0000269|PubMed:10231530,
FT                                ECO:0000269|PubMed:10840044}.
FT   SITE        170    170       Important for catalytic activity.
FT                                {ECO:0000305}.
FT   MOD_RES      80     80       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q61425}.
FT   MOD_RES      81     81       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q61425}.
FT   MOD_RES      81     81       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q61425}.
FT   MOD_RES      87     87       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q61425}.
FT   MOD_RES      87     87       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q61425}.
FT   MOD_RES     125    125       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q61425}.
FT   MOD_RES     136    136       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q61425}.
FT   MOD_RES     136    136       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q61425}.
FT   MOD_RES     179    179       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q61425}.
FT   MOD_RES     185    185       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     185    185       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q61425}.
FT   MOD_RES     192    192       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q61425}.
FT   MOD_RES     192    192       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q61425}.
FT   MOD_RES     202    202       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     202    202       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q61425}.
FT   MOD_RES     206    206       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q61425}.
FT   MOD_RES     212    212       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q61425}.
FT   MOD_RES     212    212       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q61425}.
FT   MOD_RES     241    241       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     241    241       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q61425}.
FT   MOD_RES     312    312       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     312    312       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q61425}.
FT   VAR_SEQ       1      1       M -> MGRAGLEAPPPPCGVTGTPGARGLQGRVGPRPQSLA
FT                                FRGCLPRASSLPGSPRCRRRCHTM (in isoform 2).
FT                                {ECO:0000303|Ref.2}.
FT                                /FTId=VSP_016551.
FT   VAR_SEQ     236    236       R -> RDFQTCGDSNSGLGFSLK (in isoform 2 and
FT                                isoform 3). {ECO:0000303|Ref.2}.
FT                                /FTId=VSP_016552.
FT   VARIANT      40     40       A -> T (in HADH deficiency;
FT                                dbSNP:rs137853101). {ECO:0000269|Ref.13}.
FT                                /FTId=VAR_024079.
FT   VARIANT      57     57       D -> E (in HADH deficiency;
FT                                dbSNP:rs137853102). {ECO:0000269|Ref.13}.
FT                                /FTId=VAR_024080.
FT   VARIANT      86     86       L -> P (in dbSNP:rs4956145).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:8687463,
FT                                ECO:0000269|Ref.2, ECO:0000269|Ref.3}.
FT                                /FTId=VAR_026764.
FT   VARIANT     152    152       Q -> H (in dbSNP:rs1051519).
FT                                {ECO:0000269|PubMed:8687463}.
FT                                /FTId=VAR_055701.
FT   VARIANT     258    258       P -> L (in HHF4; loss of activity;
FT                                dbSNP:rs137853103).
FT                                {ECO:0000269|PubMed:11489939}.
FT                                /FTId=VAR_024081.
FT   HELIX         1     11       {ECO:0000244|PDB:3RQS}.
FT   HELIX        14     22       {ECO:0000244|PDB:3RQS}.
FT   STRAND       29     33       {ECO:0000244|PDB:1F0Y}.
FT   HELIX        37     48       {ECO:0000244|PDB:1F0Y}.
FT   STRAND       52     56       {ECO:0000244|PDB:1F0Y}.
FT   HELIX        60     79       {ECO:0000244|PDB:1F0Y}.
FT   STRAND       82     84       {ECO:0000244|PDB:1F0Y}.
FT   HELIX        86     98       {ECO:0000244|PDB:1F0Y}.
FT   STRAND      100    104       {ECO:0000244|PDB:1F0Y}.
FT   HELIX       106    109       {ECO:0000244|PDB:1F0Y}.
FT   HELIX       110    112       {ECO:0000244|PDB:3HAD}.
FT   STRAND      114    118       {ECO:0000244|PDB:1F0Y}.
FT   HELIX       124    134       {ECO:0000244|PDB:1F0Y}.
FT   TURN        135    137       {ECO:0000244|PDB:1F0Y}.
FT   STRAND      143    146       {ECO:0000244|PDB:1F0Y}.
FT   STRAND      149    151       {ECO:0000244|PDB:1F0Y}.
FT   HELIX       153    157       {ECO:0000244|PDB:1F0Y}.
FT   HELIX       163    165       {ECO:0000244|PDB:1F0Y}.
FT   STRAND      166    171       {ECO:0000244|PDB:1F0Y}.
FT   TURN        175    177       {ECO:0000244|PDB:1F0Y}.
FT   STRAND      180    184       {ECO:0000244|PDB:1F0Y}.
FT   HELIX       191    203       {ECO:0000244|PDB:1F0Y}.
FT   STRAND      207    211       {ECO:0000244|PDB:1F0Y}.
FT   TURN        215    218       {ECO:0000244|PDB:1F0Y}.
FT   HELIX       219    235       {ECO:0000244|PDB:1F0Y}.
FT   HELIX       241    252       {ECO:0000244|PDB:1F0Y}.
FT   HELIX       258    265       {ECO:0000244|PDB:1F0Y}.
FT   HELIX       267    279       {ECO:0000244|PDB:1F0Y}.
FT   TURN        280    283       {ECO:0000244|PDB:1F0Y}.
FT   HELIX       285    287       {ECO:0000244|PDB:1F0Y}.
FT   HELIX       291    298       {ECO:0000244|PDB:1F0Y}.
FT   TURN        304    307       {ECO:0000244|PDB:1F0Y}.
FT   STRAND      308    312       {ECO:0000244|PDB:1F0Y}.
SQ   SEQUENCE   314 AA;  34294 MW;  0C6F7C01BBCE646A CRC64;
     MAFVTRQFMR SVSSSSTASA SAKKIIVKHV TVIGGGLMGA GIAQVAAATG HTVVLVDQTE
     DILAKSKKGI EESLRKVAKK KFAENLKAGD EFVEKTLSTI ATSTDAASVV HSTDLVVEAI
     VENLKVKNEL FKRLDKFAAE HTIFASNTSS LQITSIANAT TRQDRFAGLH FFNPVPVMKL
     VEVIKTPMTS QKTFESLVDF SKALGKHPVS CKDTPGFIVN RLLVPYLMEA IRLYERGDAS
     KEDIDTAMKL GAGYPMGPFE LLDYVGLDTT KFIVDGWHEM DAENPLHQPS PSLNKLVAEN
     KFGKKTGEGF YKYK
//
